As homozygous inactivating deletions of Polk are relatively frequently observed in human cancers, such as prostate, ovarian, and pancreatic cancers as well as melanoma (Figure 4K), our data suggest that these patients may benefit from treatments with platinating agents. The gene discussed is POLK; the disease is familial pancreatic carcinoma.